Nihon Kohden Corp
TSE:6849

Watchlist Manager
Nihon Kohden Corp Logo
Nihon Kohden Corp
TSE:6849
Watchlist
Price: 1 632 JPY -3.35% Market Closed
Market Cap: ¥279B

Gross Margin

51.9%
Current
Improving
by 0.6%
vs 3-y average of 51.3%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
51.9%
=
Gross Profit
¥119.8B
/
Revenue
¥231B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
51.9%
=
Gross Profit
¥119.8B
/
Revenue
¥231B

Peer Comparison

Country Company Market Cap Gross
Margin
JP
Nihon Kohden Corp
TSE:6849
265B JPY
Loading...
US
Abbott Laboratories
NYSE:ABT
196.7B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
173.6B USD
Loading...
US
Stryker Corp
NYSE:SYK
147B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
124.2B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
110.6B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
45.7B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
50.6B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49.3B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
50.3B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.4B USD
Loading...

Market Distribution

Higher than 80% of companies in Japan
Percentile
80th
Based on 6 625 companies
80th percentile
51.9%
Low
-179.8% — 21.8%
Typical Range
21.8% — 42.3%
High
42.3% — 18 197.9%
Distribution Statistics
Japan
Min -179.8%
30th Percentile 21.8%
Median 30.6%
70th Percentile 42.3%
Max 18 197.9%

Nihon Kohden Corp
Glance View

Market Cap
279B JPY
Industry
Health Care

Nihon Kohden Corp., founded in 1951, has evolved into a pioneering force in the medical technology landscape, blending innovation with a storied heritage. This Tokyo-based firm established its foothold by developing advanced medical electronic devices, initially focusing on EEG (electroencephalography) machines. As medical science rapidly advanced, Nihon Kohden expanded its portfolio to include a range of diagnostic and monitoring equipment. Today, the company's product line encompasses patient monitors, defibrillators, electrocardiographs, and clinical information systems, serving various healthcare domains. This focus on critical care and diagnostics creates consistent demand across global hospitals and clinics, reinforcing its reputation as a dependable partner in medical excellence. Financially, Nihon Kohden's business model thrives on a dual revenue structure: product sales and after-sales service. By manufacturing and distributing complex equipment directly and through a network of distributors, the company captures a significant share of initial capital expenditure in healthcare institutions. Furthermore, it enhances this income by offering ongoing equipment maintenance, training, and customer support, forming long-term relationships with healthcare providers. These services ensure not only a steady revenue stream beyond the initial sale but also brand loyalty and trust in an industry where precision and reliability are paramount. As it continues to innovate, Nihon Kohden's commitment to addressing the evolving needs of healthcare practitioners fortifies its market position and operational success.

Intrinsic Value
1 810.65 JPY
Undervaluation 10%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
51.9%
=
Gross Profit
¥119.8B
/
Revenue
¥231B
What is Nihon Kohden Corp's current Gross Margin?

The current Gross Margin for Nihon Kohden Corp is 51.9%, which is above its 3-year median of 51.3%.

How has Gross Margin changed over time?

Over the last 3 years, Nihon Kohden Corp’s Gross Margin has increased from 51.3% to 51.9%. During this period, it reached a low of 49.6% on Jun 30, 2024 and a high of 53.1% on Jun 30, 2025.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett